GENELUX Corp (GNLX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US36870H1032
GENELUX Corp financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 8,000.00 USD |
| Operating income | -33.21 m USD |
| EBIT | -32.86 m USD |
| Net income | -32.15 m USD |
| Diluted EPS – continuing operations | -0.86 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GENELUX Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
More stocks
- Rayence Co. Ltd (228850.KQ)
- SUNHYDROGEN, INC. (HYSR)
- Taitien Electronics Co Ltd (8289.TWO)
- Trident Digital Tech Holdings Ltd (TDTH)
- First Bancshares Inc (FBSI)
- INTERGROUP CORP (INTG)
- ASolid Technology Co Ltd (6485.TWO)
- Champion Building Materials Co Ltd (1806.TW)
- BUDA JUICE, INC. (BUDA)
- Silvercrest Asset Management Group Inc. (SAMG)
- Taeyang Metal (004100.KS)
- East Tender Opto (6588.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.